Drug Trial Radar · NCT06097728
MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural Mesothelioma
Last checked: Nov 19, 2026Latest source record: Oct 23, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
863
Actual
Start
Nov 9, 2023
Primary completion
Nov 16, 2028
Study completion Nov 16, 2028
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Oct 24, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a phase III, randomized, open-label, multicenter, global study to determine the efficacy and safety of Volrustomig (MEDI5752) + Carboplatin + Pemetrexed vs the investigator's choice of platinum + Pemetrexed or Nivolumab + Ipilimumab in participants with unresectable pleural mesothelioma.
Conditions
- Unresectable Pleural Mesothelioma
Interventions
VolrustomigDrug
MEDI5752: Administered as IV infusion
PemetrexedDrug
Alimta: Administered as IV infusion
CarboplatinDrug
Paraplatin: Administered as IV infusion
CisplatinDrug
Platinol: Administered as IV infusion
NivolumabDrug
Opdivo: Administered as IV infusion
IpilimumabDrug
Yervoy: Administered as IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS) in experimental arm relative to comparator armTime frame: up to approximately 61 months
Locations
151 sites in 21 countries. Site status is shown where the registry gives one.
Research Site
Santa Rosa, California
Research Site
Aurora, Colorado
Research Site
Jacksonville, Florida
Research Site
Atlanta, Georgia
Research Site
Chicago, Illinois
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Commack, New York
Research Site
Columbus, Ohio
Research Site
Portland, Oregon
Research Site
Portland, Oregon
Research Site
Philadelphia, Pennsylvania
Research Site
Houston, Texas
Research Site
Fairfax, Virginia
Research Site
Chermside, Australia
Research Site
Clayton, Australia
Research Site
Melbourne, Australia
Research Site
Nedlands, Australia
Research Site
Westmead, Australia
Research Site
Anderlecht, Belgium
Research Site
Antwerp, Belgium
Research Site
Ghent, Belgium
Research Site
Hasselt, Belgium
Research Site
Sint-Niklaas, Belgium
Research Site
Barretos, Brazil
Research Site
Fortaleza, Brazil
Research Site
Porto Alegre, Brazil
Research Site
Rio de Janeiro, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site
Edmonton, Alberta, Canada
Research Site
Ottawa, Ontario, Canada
Research Site
Toronto, Ontario, Canada
Research Site
Montreal, Quebec, Canada
Research Site
Québec, Quebec, Canada
Research Site
Beijing, China
Research Site
Beijing, China
Research Site
Changsha, China
Research Site
Chengdu, China
Research Site
Guangzhou, China
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.